摘要
肝癌已成为最常见、最致命的恶性肿瘤之一。近年来,基于靶向性和免疫性药物的第三阶段试验取得了较好结果,更多针对特定肿瘤代谢通路和免疫检查点的药物正在临床研发中,一些药物已经被证明可以改善肝癌患者的预后。肝癌患者的治疗方案正在迅速改变。本文对肝癌患者靶向治疗和免疫治疗药物的机制、副反应、疗效及正在进行的研究作一阐述。
Hepatocellular carcinoma(HCC)has become one of the most common and deadly malignancies.In recent years,the third phase of drugs based on target and immunity has obtained better results,more drugs focusing on specific tumor metabolic pathways and immune checkpoints are under clinical development,and some drugs have been identified that can improve the prognosis of liver cancer patients.Treatments of HCC changes rapidly.This article reviewed the mechanism,side effects,efficacy and ongoing research of targeted therapy and immunotherapy drugs for HCC.
作者
胡铭洋
吴绮楠
吴永忠
Hu Mingyang;Wu Qinan;Wu Yongzhong({Department of Endocrine Nephropathy,Chongqing University Cancer Hospital)
出处
《重庆医科大学学报》
CAS
CSCD
北大核心
2019年第12期1547-1552,F0002,共7页
Journal of Chongqing Medical University
基金
国家自然科学基金面上资助项目(编号:81370885)
重庆市科技局科研机构绩效激励引导专项面上资助项目(编号:cstc2019jxjl0018)
关键词
肝癌
酪氨酸激酶抑制剂
免疫检测点抑制剂
hepatocellular carcinomal
tyrosine kinase inhibitor
immuno-checkpoint inhibitors
